What is Zenith Capital Corp?
, a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 15.93M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.